Brainlab: The Largest IPO of the Year
Brainlab, a leading medical technology company based in Munich, plans one of the most significant IPOs of the year. The listing of shares on the regulated market (Prime Standard) of the Frankfurt Stock Exchange is scheduled for early July, despite current uncertainty in the capital markets.
Background and Objectives
Brainlab was founded in 1989 by Stefan Vilsmeier and is known for its innovative software solutions in medical technology, particularly in the fields of surgery and tumor radiation therapy. The company aims to generate up to 200 million euros through the IPO by issuing new shares. Additionally, secondary shares will be offered, including those from the company’s founder.
Financial Situation and Plans
In the first half of 2025, Brainlab achieved sales of 239 million euros and an operating profit margin of 22.4 percent. The record sales for 2023 were over 450 million euros, reflecting an 11 percent growth. The proceeds from the IPO are intended for expansion into new application fields and to strengthen the balance sheet to enhance strategic and financial flexibility for long-term growth.
Valuation and Market Position
The targeted valuation of Brainlab is around two billion euros. The company employs approximately 2,000 people, and its technologies are used in about 4,000 healthcare facilities across 120 countries. Brainlab is particularly known for its software solutions, such as the “digital twin” for surgery, which integrates patient data with a 3D anatomy model.
Relevance for Investors
The IPO of Brainlab is of high relevance for investors in the German-speaking region, as it is one of the most significant IPOs of the year. Despite the uncertain capital market situation, Brainlab shows a strong market position with its record sales and expansion plans. The listing on the Prime Standard of the Frankfurt Stock Exchange offers investors the opportunity to invest in an innovative company with strong growth potential.